Pharma Journalist -

AbbVie announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI, 600 mg intravenous (IV) induction and 360 mg…
Read More...

AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with…
Read More...

UCB, a global biopharmaceutical company, and Chiesi Group, the international research-focused pharmaceutical and healthcare group, are pleased to announce that they have entered into an…
Read More...

BONE THERAPEUTICS, the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term…
Read More...

As we have with previous emerging COVID-19 variants, the U.S. Food and Drug Administration is actively working with our federal partners, international regulators and medical product…
Read More...

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced…
Read More...

Kymera Therapeutics, Inc. a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced…
Read More...

Valneva SE and IDT Biologika announced their collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001. This follows last week’s announcement that…
Read More...

Quell Therapeutics Ltd ("Quell"), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system,…
Read More...

Thermo Fisher Scientific Inc. confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit*, and TaqPath COVID-19 CE-IVD RT-PCR Kit*, which test for the presence of…
Read More...